Highly potent antiviral drug candidates targeting SARS-CoV-2 nsp3 and nsp5.

Highly potent antiviral drug candidates targeting SARS-CoV-2 nsp3 and nsp5.

Publication date: Aug 04, 2026

Faced with the repeated emergence of three major epidemics caused by coronaviruses over the past 20 years (SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019), the development of novel antiviral treatments has become a critical public health priority. In this study, molecular modeling tools, including docking, virtual screening, and molecular dynamics, were combined with databases to identify potential inhibitors of SARS-CoV-2 non-structural proteins nsp3 and nsp5. High-throughput virtual screening of the ZINC15 database led to the identification of two promising small molecules, Amb929 and Amb701, targeting nsp3 and nsp5, respectively. In vitro assays confirmed that both compounds inhibited SARS-CoV-2 replication, with Amb929 demonstrating superior antiviral efficacy and lower cytotoxicity compared to Amb701. Using a human airway epithelium model, Amb929 exhibited strong antiviral activity, a high selectivity index, and significant inhibition of viral replication, highlighting its ex vivo potential as a promising candidate for the development of effective anti-coronavirus drugs.

Open Access PDF

Concepts Keywords
Antiviral Coronavirus
Coronaviruses COVID-19
Effective Drug design
Pharmacother HCoV-229E
Zinc15 Nsp3
Nsp5
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *